Efficacy
EKOS has been shown to yield safe and effective results for acute, massive and submassive PE.
- Reduces RV/LV ratio by more than 23% on average in as little as 2 hours
- Reduces PA pressures by 28% (at 48 hours)
- Up to 88-92% less thrombolytic dose than standard systemic treatment 1,2
- Minimized risk of bleeding
| Study | RV/LV reduction |
| ULTIMA | 23% (24 hours) |
| SEATTLE II | 25% (48 hours) |
| OPTALYSE | 23-26% (48 hours) |
Safety
EKOS has been shown to have a low risk of bleeding and ICH.
- Low major bleeding rate across studies (1.44%)
- ICH rate of 0.4% across major studies, two with 0 instances of ICH
| Study | Safety | Total dose |
| ULTIMA | 0% (Major bleed) | 0 (ICH) | 20mg |
| SEATTLE II | 0.67% (Severe bleed) | 0 (ICH) | 24mg |
| OPTALYSE | 3% (Major bleed) | 1 (ICH) | 4/8mg-12/24mg |
2. Konstantinides S, Geibel A, Heusel G, et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med.2002;347:1143–1150.